← Human Trials & Peer-Reviewed Studies
OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS
Plain-language guide to PMID 26307903 (2015): open-label randomized controlled trial study of Insulin (regular human), insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 26307903
- Journal
- Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Mari A et al. (5 authors)
- DOI
- 10.4158/EP15898.OR
What This Study Did, in Plain Language
What Was Tested
Researchers studied Insulin (regular human) in the context of insulin resistance, prediabetes & type 2 diabetes in this randomized controlled trial publication.
Who Took Part
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
A subset of patients in a 24-week, open-label, randomized trial comparing thrice-daily (n = 14/162) versus twice-daily (n = 11/163) human regular U-500 insulin (U-500R) underwent mixed meal tolerance testing at baseline and endpoint.
How the Study Was Run
The researchers set it up as a randomized and open-label study.
The participants were allocated by chance, so the Insulin (regular human) group and the comparison group should start out alike.
Everyone knew when Insulin (regular human) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
Primary outcome measure was ratio of area under the curve (AUC) for C-peptide to glucose (AUCC-peptide/AUCglucose) at 24-week endpoint.
What Was Measured
The subject headings attached to it are Blood Glucose, Calibration, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin Resistance, Insulin, Regular, Human and Insulin-Secreting Cells.
What This Means in Plain Language
The paper is a randomized and open-label study of Insulin (regular human) in people with insulin resistance, prediabetes & type 2 diabetes.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2015 (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists), a journal based in United States.
More context: the Insulin (regular human) compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
Insulin (regular human): The 51-amino-acid pancreatic hormone that lowers blood glucose; this page covers regular (short-acting) insulin studied in human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.